Control de la hipercolesterolemia en España: una misma situación con diferentes realidades autonómicas

Pedro-Botet, Juan; Plana, Núria; Mostaza, José María; Gómez-Doblas, Juan José; Fernández Olmo, María Rosa; Escobar Cervantes, Carlos; Díaz-Díaz, José Luis; Campuzano Ruiz, Raquel; Valdivielso, Pedro; Cosín-Sales, Juan.
Clín. investig. arterioscler. (Ed. impr.) ; 35(5): 219-225, sep.-oct. 2023. mapas, graf
Artículo en Español | IBECS (España) | ID: ibc-226508

Documentos relacionados

  1. Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease.
  2. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
  3. An update on trials of novel lipid-lowering drugs.
  4. Pharmacotherapy of the Lipid-Lowering Drugs: Update on Efficacy and Risk.
  5. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lipoprotein(a): An Update on New Therapies.
  6. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
  7. New Era of Lipid-Lowering Drugs.
  8. Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events.
  9. Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation.
  10. Seaweeds and Their Natural Products for Preventing Cardiovascular Associated Dysfunction.